1 |
中华医学会皮肤性病学分会银屑病专业委员会. 中国银屑病诊疗指南(2023版)[J]. 中华皮肤科杂志, 2023, 56(7): 573-625.
|
2 |
Griffiths CEM, Armstrong AW, Gudjonsson JE, et al. Psoriasis[J]. Lancet, 2021, 397(10281): 1301-15.
|
3 |
Schett G, McInnes IB, Neurath MF. Reframing immune-mediated inflammatory diseases through signature cytokine hubs[J]. N Engl J Med, 2021, 385(7): 628-39.
|
4 |
Hirobe S, Yamasaki T, Ito S, et al. Transcutaneous administration of imiquimod promotes T and B cell differentiation into effector cells or plasma cells[J]. Pharmaceutics, 2022, 14(2): 385.
|
5 |
Cyster JG, Allen CDC. B cell responses: cell interaction dynamics and decisions[J]. Cell, 2019, 177(3): 524-40.
|
6 |
Mastellos DC, Hajishengallis G, Lambris JD. A guide to complement biology, pathology and therapeutic opportunity[J]. Nat Rev Immunol, 2024, 24(2): 118-41.
|
7 |
Qiao P, Zhi DL, Yu C, et al. Activation of the C3a anaphylatoxin receptor inhibits keratinocyte proliferation by regulating keratin 6, keratin 16, and keratin 17 in psoriasis[J]. FASEB J, 2022, 36(5): e22322.
|
8 |
Zheng QY, Liang SJ, Xu F, et al. C5a/C5aR1 pathway is critical for the pathogenesis of psoriasis[J]. Front Immunol, 2019, 10: 1866.
|
9 |
蔺 瑞, 边海旭, 郭 超, 等. 五谷虫的药理作用研究进展[J]. 中国药房, 2017, 289(4): 558-61. DOI: 10.6039/j.issn.1001-0408.2017.04.35
|
10 |
张 玮, 石晓丽, 刘一凡, 等. 中药五谷虫活性肽-酶类化学成分研究进展[J]. 时珍国医国药, 2022, 33(8): 1978-82.
|
11 |
Shamloul G, Khachemoune A. Reappraisal and updated review of maggot debridement therapy in chronic lower extremity ulcers[J]. Int J Dermatol, 2023, 62(7): 962-8.
|
12 |
杭小涵, 李 雪, 李 楠, 等. 基于p38MAPK/NF-κB信号通路探讨外用应急软膏治疗银屑病的机制研究[J]. 世界临床药物, 2023, 44(3): 215-9, 251. DOI: 10.13683/j.wph.2023.03.004
|
13 |
Peng F, Zong J, Zhao T, et al. Anti-inflammatory and immunomodulatory effects of polysaccharide extracted from Wuguchong (maggot) on 2,4-dinitrochlorobenzene-induced atopic dermatitis in mice[J]. Front Pharmacol, 2023, 14: 1119103.
|
14 |
van der Plas MJ, van der Does AM, Baldry M, et al. Maggot excretions/secretions inhibit multiple neutrophil pro-inflammatory responses[J]. Microbes Infect, 2007, 9(4): 507-14.
|
15 |
Cazander G, Schreurs MW, Renwarin L, et al. Maggot excretions affect the human complement system[J]. and, 2012, 20(6): 879-86.
|
16 |
张海龙, 安月鹏, 崔晓倩, 等. 通过调控滤泡性辅助性T细胞亚群研究蜈蚣败毒饮治疗银屑病模型鼠的机制[J]. 中国皮肤性病学杂志, 2022, 36(8): 890-7. DOI: 10.13735/j.cjdv.1001-7089.202111204
|
17 |
Zhao F, Wang YJ, Zuo HJ, et al. Cyclin-Dependent kinase 9 (CDK9) inhibitor Atuveciclib ameliorates Imiquimod-Induced Psoriasis-Like dermatitis in mice by inhibiting various inflammation factors via STAT3 signaling pathway[J]. Int Immunopharmacol, 2024, 129: 111652.
|
18 |
郭智玮, 晋红中. 银屑病伴瘙痒的临床特点、发病机制及治疗研究进展[J]. 中华皮肤科杂志, 2020, 53(12): 1029-32. DOI: 10.35541/cjd.20190683
|
19 |
何亚男, 蔡 翔, 邱百怡, 等. 穿心莲内酯调节cGAS-STING信号通路对银屑病小鼠的治疗作用[J]. 天津医药, 2024, 52(4): 379-86.
|
20 |
Sulthana S, Chary PS, Bhavana V, et al. Development and evaluation emulgel for effective management of the imiquimod-induced psoriasis[J]. Inflammopharmacology, 2023, 31(1): 301-20.
|
21 |
Zhang S, Zhang J, Yu JJ, et al. Hyperforin ameliorates imiquimod-induced psoriasis-like murine skin inflammation by modulating IL-17A-producing γδ T cells[J]. Front Immunol, 2021, 12: 635076.
|
22 |
Zhang YJ, Shi YQ, Lin JX, et al. Immune cell infiltration analysis demonstrates excessive mast cell activation in psoriasis[J]. Front Immunol, 2021, 12: 773280.
|
23 |
张 喻, 向雪川, 周正繁, 等. 龙珠软膏对银屑病模型小鼠治疗作用的研究[J]. 中国医院药学杂志, 2023, 43(8): 897-902, 909. DOI: 10.13286/j.1001-5213.2023.08.12
|
24 |
Syzon OO, Dashko MO, Fedorova UV. Modern specific features and therapy of psoriasis and arthropathic psoriasis courses[J]. Wiad Lek, 2018, 71(2 pt 1): 322-5.
|
25 |
Giang J, Seelen MAJ, van Doorn MBA, et al. Complement activation in inflammatory skin diseases[J]. Front Immunol, 2018, 9: 639.
|
26 |
Costabile M. Measuring the 50% haemolytic complement (CH50) activity of serum[J]. J Vis Exp, 2010(37): 1923.
|
27 |
Laumonnier Y, Karsten CM, Köhl G, et al. Characterization of anaphylatoxin receptor expression and C3a/C5a functions in anaphylatoxin receptor reporter mice[J]. Curr Protoc Immunol, 2020, 130(1): e100.
|
28 |
Ling M, Murali M. Analysis of the complement system in the clinical immunology laboratory[J]. Clin Lab Med, 2019, 39(4): 579-90.
|
29 |
Hashimoto T, Tsuruta D, Yasukochi A, et al. Granular C3 dermatosis[J]. Acta Derm Venereol, 2016, 96(6): 748-53.
|
30 |
Ring J, Senter T, Cornell RC, et al. Complement and immunoglobulin deposits in the skin of patients with atopic dermatitis[J]. Br J Dermatol, 1978, 99(5): 495-501.
|
31 |
Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review[J]. JAMA, 2020, 323(19): 1945-60.
|
32 |
Liu LJ, Zhang HL, Tang XR, et al. Geniposide ameliorates psoriatic skin inflammation by inhibiting the TLR4/MyD88/NF‑κB p65 signaling pathway and MMP9[J]. Int Immunopharmacol, 2024, 133: 112082.
|